MYX settles US patent litigation re Imvexxy with Sun Pharma
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Mayne Pharma Group Ltd. has announced the settlement of US patent litigation regarding IMVEXXY with Sun Pharma, resolving ongoing Paragraph IV litigation related to FDA Orange Book patents. The settlement establishes a pathway for the potential market entry of a generic version of IMVEXXY by Sun Pharma, with an agreed entry date. This agreement underscores the validity of Mayne Pharma's patent portfolio for IMVEXXY, which is crucial for the company's Women’s Health business.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings CallMayne Pharma Group Ltd. on 6ix
Story so far
Earlier from Mayne Pharma
- Mayne Pharma announces legal settlement
- Date for Annual General Meeting
- MYX signs licence agreement for Blissel in Australia
- Notification of cessation of securities - MYX
- Notification regarding unquoted securities - MYX
Later from Mayne Pharma
- Fulfilment of Imvexxy post-marketing study requirements
- Trading Halt
- Supreme Court Decision in Cosette Proceedings
- MYX settles US patent litigation re Imvexxy with Teva USA
- 2026 Notice of Annual General Meeting and shareholder pack
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma